Skip to main content

Table 1 Baseline characteristics of treatment group and placebo

From: Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy

 

Treatment (n=17)

Placebo (n=17)

Gender (males: females)

13: 4

14: 3

Age (years) (SD)

74.5 (4.2)

73.5 (4.0)

Smoking (n/total)

1/17

1/17

Hypertension (n/total)

12/17

13/17

BMI (kg/m2) (SD)

25.6 (3.4)

26.8 (8.3)

Chronic AF (n/total)

11/17

9/17

Duration of AF (years)(SD)

13.5 (15.0)

14.0 (19.3)

  1. Data as mean (SD). AF, atrial fibrillation; BMI, body mass index;n, number of patients; SD, standard deviation.